The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...
Hosted on MSN20h
As Another Obesity-Fighting Drug Takes Center Stage, A Nutrition Expert Warns That Weight Loss Shouldn't Be The Only GoalZepbound is the newest addition to the weight loss drug arena. In November 2023, it joined the list of obesity-fighting drugs – administered as an injection – to be approved by the U.S. Food and Drug ...
Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...
San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...
The drug Zepbound might not have the same name recognition as Ozempic, but it's another in the class to treat obesity and ...
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...
Additionally, Lilly closed out the year by snagging a key new approval for Zepbound in obstructive sleep apnea (OSA), making ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback